Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43862   clinical trials with a EudraCT protocol, of which   7285   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2006-006739-36
    Sponsor's Protocol Code Number:20060314
    National Competent Authority:Sweden - MPA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2007-04-12
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSweden - MPA
    A.2EudraCT number2006-006739-36
    A.3Full title of the trial
    A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal Cancer
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
    A.4.1Sponsor's protocol code number20060314
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT00508404
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAmgen Inc
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAmgen Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAmgen (EUROPE) GmbH
    B.5.2Functional name of contact pointIHQ Medical Info – Clinical Trials
    B.5.3 Address:
    B.5.3.1Street AddressDammstrasse 23, P.O. Box 1557
    B.5.3.2Town/ cityZug
    B.5.3.3Post code(CH-)6300
    B.5.3.4CountrySwitzerland
    B.5.6E-mailMedinfoInternational@amgen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Vectibix 20 mg/ml concentrate for solution for infusion
    D.2.1.1.2Name of the Marketing Authorisation holderAmgen Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePanitumumab
    D.3.2Product code AMG954
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPANITUMUMAB
    D.3.9.1CAS number 339177-26-3
    D.3.9.2Current sponsor codeAMG954
    D.3.9.3Other descriptive namePanitumumab
    D.3.9.4EV Substance CodeSUB25390
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with metastatic colorectal cancer
    E.1.1.1Medical condition in easily understood language
    Metastatic Colorectal Cancer
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10052362
    E.1.2Term Metastatic colorectal cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To estimate the effect of KRAS mutation status (wild-type versus mutant) on objective response rate and other measures of efficacy for subjects treated with panitumumab in combination with a chemotherapy regimen of irinotecan, 5- luorouracil (5-FU) and leucovorin (FOLFIRI) as 1st-line therapy for metastatic colorectal cancer (mCRC).
    E.2.2Secondary objectives of the trial
    To describe the safety profile of this combination therapy in the 1st- line setting including the incidence of AE’s and significant changes in laboratory parameters.

    Exploratory objectives:
    To explore measures of patient reported outcomes (PRO), healthcare resource utilisation and any integument and eye toxicity management scheme
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients will be eligible to participate in the study if they meet all of the criteria listed below.
    1. Ethical
    Competent to comprehend, sign, and date an IEC-approved informed consent form.

    2. Demographic
    Of either gender and aged 18 years or more.

    3. Disease-related
    •Diagnosed with histologically- or cytologically-confirmed metastatic adenocarcinoma of the colon and/or rectum.
    •Measurable disease according to modified RECIST guidelines. All sites of disease must have been evaluated within 28 days of initiating study treatment, and diagnosed by the investigator.
    •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
    •Have available paraffin-embedded tissue or unstained tumour slides from primary or metastatic tumour.

    4. Laboratory
    -Haematologic function, as follows (within seven days prior to initiating study treatment):
    • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
    • Platelet count ≥100 x 109/L.
    • Haemoglobin ≥10 g/dL.

    -Renal function, as follows (within seven days prior to initiating study treatment):
    • Creatinine ≤1.5 mg/dL.

    -Hepatic function, as follows (within seven days prior to initiating study treatment):
    • Aspartate aminotransferase (AST) ≤3 x ULN (if liver metastases ≤ 5 x ULN).
    • Alanine aminotransferase (ALT) ≤3 x ULN (if liver metastases ≤ 5 x ULN).
    • Bilirubin ≤ 2 x ULN.

    -Metabolic function, as follows (within seven days prior to initiating study treatment):
    • Magnesium ≥ lower limit of normal.
    • Calcium ≥ lower limit of normal.
    E.4Principal exclusion criteria
    Any patient exhibiting any of the criteria listed below will be excluded from the study:
    1. Disease Related
    • Central nervous system metastases (Exception: subjects who have been treated, have asymptomatic central nervous system metastases, and have been off steroids for at least 30 days before initiating study treatment are eligible).

    2. Therapies
    • Prior systemic therapy for the treatment of metastatic colorectal carcinoma with the exception of adjuvant fluoropyrimidine-based chemotherapy given at least six months prior to initiating study treatment.

    • Prior anti-EGFr antibody therapy (e.g.: cetuximab) or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g.: erlotinib).

    • Prior radiotherapy within 14 days prior to screening, and for which all signs of early radiological toxicity have not abated.

    3. General
    • Significant cardiovascular disease including unstable angina or myocardial infarction within six months before initiating study treatment or a history of ventricular arrhythmia.

    • History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan.

    • Treatment for systemic infection within 14 days before initiating study treatment.

    • Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as > 4 loose stools per day).

    • History of Gilbert’s syndrome or dihydropyrimidine deficiency.

    • History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results.

    • Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection.

    • Any co-morbid disease that would increase risk of toxicity.

    • Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures.

    • Any investigational agent within 30 days before initiation of study treatment.

    • Must not have had a major surgical procedure within 28 days prior to initiation of study treatment.

    • Subject who is pregnant or breast-feeding.

    • Woman or man of childbearing potential not consenting to use adequate contraceptive precautions i.e. double barrier contraceptive methods (e.g. diaphragm plus condom) during the course of the study and for six months after the last study drug administration for women, and one month for men.

    • Subject unwilling or unable to comply with study requirements.
    E.5 End points
    E.5.1Primary end point(s)
    Objective response rate (ORR): Incidence of either a confirmed complete or partial response; subjects prematurely discontinuing without a post-baseline tumour response assessment or subjects who do not meet the criteria for an objective response by the analysis data cut-off date will be considered
    non-responders.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary analysis will be performed using a data cut-off approximately 12 months after the last subject was enrolled (completed). The final analysis will be performed when all subjects have discontinued the treatment phase and completed the safety follow-up visit.
    E.5.2Secondary end point(s)
    Disease control rate (DCR): Incidence of either a confirmed complete or partial response, or stable disease (SD); subjects prematurely discontinuing without a post-baseline tumour response assessment or subjects who do not meet the
    criteria for disease control by the analysis data cut-off date will be
    considered to not have disease control.
    • Duration of response (DOR): Calculated only for those subjects who have a confirmed complete or partial response, time from first confirmed response to first observed progression. For subjects who respond and have not progressed by the analysis data cut-off date, duration of response will be censored at their
    last evaluable disease assessment date.
    • Time to response (TTR): Time from enrolment date to first confirmed complete or partial response; subjects with a best response of stable disease by the analysis data cut-off date will be censored at their last assessment of SD and subjects with all other categories of best response will be censored at the
    maximum observed time to a first confirmed response among all
    responders.
    • Progression-free survival time (PFS): The time from enrolment date to date of first observed progression or death (whichever comes first). Subjects who are alive and have not progressed by the analysis data cut-off date will be censored at the last evaluable disease assessment date.
    • Time to progression (TTP): Time from enrolment date to date of first observed progression. For subjects who have not progressed by the analysis data cut- off date, time to progressive disease will be censored at their last evaluable disease assessment date.
    • Duration of stable disease (DoSD): Calculated only for subjects with a best response of stable disease. Time from enrolment to first observed PD. For subjects who have not progressed by the analysis data cut-off date, duration of SD will be censored at their last evaluable disease assessment date.
    • Time to treatment failure: Time from enrolment to the date the decision was made to end the treatment phase for any reason. For subjects who remain in the treatment phase by the analysis data cut-off date, time to treatment failure will be censored at the date of their last on-study assessment.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The primary analysis will be performed using a data cut-off approximately 12 months after the last subject was enrolled (completed). The final analysis will be performed when all subjects have discontinued the treatment phase and completed the safety follow-up visit.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA41
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    All subjects will attend a safety follow-up visit approximately 56 days after ending the treatment phase. This is the end of the study for each patient.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 75
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 79
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 150
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Not different from the expected normal treatment of that condition
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2007-05-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2007-06-26
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2012-06-12
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 11:54:58 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA